TY - JOUR
T1 - Platelet-derived growth factor-BB
T2 - a stimulus for cytokine production by orbital fibroblasts in Graves' ophthalmopathy
AU - van Steensel, Leendert
AU - Paridaens, Dion
AU - Dingjan, Gemma M
AU - van Daele, Paul L A
AU - van Hagen, P Martin
AU - Kuijpers, Robert W A M
AU - van den Bosch, Willem A
AU - Drexhage, Hemmo A
AU - Hooijkaas, Herbert
AU - Dik, Willem A
PY - 2010/2
Y1 - 2010/2
N2 - PURPOSE: Graves' ophthalmopathy (GO) is characterized by the infiltration of immune cells into the orbit, a process in which cytokines play a central role. Orbital fibroblasts are potent producers of cytokines on different stimuli. Recently, the authors showed increased expression of the PDGF-B chain in GO orbital tissue. The dimeric PDGF-BB molecule has been described to activate the NF-kappaB pathway, which is well recognized for its role in regulating cytokine production. This study was conducted to determine the role of PDGF-BB in the production of proinflammatory cytokines by orbital fibroblasts in GO.METHODS: Orbital, lung, and skin fibroblasts were stimulated with PDGF-BB, and cytokine (IL-1beta, IL-6, IL-8, IL-16, CCL2, CCL5, CCL7, TNF-alpha) production was measured by ELISA. Involvement of NF-kappaB activation through PDGF signaling was investigated by electrophoretic mobility shift assay, specific NF-kappaB inhibitors, and the PDGF-receptor kinase inhibitor imatinib mesylate.RESULTS: IL-6, IL-8, CCL2, CCL5, and CCL7 production by orbital fibroblasts was increased by PDGF-BB stimulation, whereas IL-16, IL-1beta, and TNF-alpha production was not affected. PDGF-BB induced NF-kappaB activity in orbital fibroblasts, and both NF-kappaB inhibitors and imatinib mesylate reduced PDGF-BB-induced cytokine production. Similar, but less vigorous, effects of PDGF-BB on cytokine production were observed in lung and skin fibroblasts.CONCLUSIONS: PDGF-BB is a potent inducer of proinflammatory cytokines via the NF-kappaB pathway in orbital fibroblasts, whereas cytokine production by fibroblasts from other anatomic locations showed a moderate response. These data suggest a possible role for PDGF-BB in regulating orbital inflammation in GO and identify the PDGF signaling cascade as a therapeutic target in GO.
AB - PURPOSE: Graves' ophthalmopathy (GO) is characterized by the infiltration of immune cells into the orbit, a process in which cytokines play a central role. Orbital fibroblasts are potent producers of cytokines on different stimuli. Recently, the authors showed increased expression of the PDGF-B chain in GO orbital tissue. The dimeric PDGF-BB molecule has been described to activate the NF-kappaB pathway, which is well recognized for its role in regulating cytokine production. This study was conducted to determine the role of PDGF-BB in the production of proinflammatory cytokines by orbital fibroblasts in GO.METHODS: Orbital, lung, and skin fibroblasts were stimulated with PDGF-BB, and cytokine (IL-1beta, IL-6, IL-8, IL-16, CCL2, CCL5, CCL7, TNF-alpha) production was measured by ELISA. Involvement of NF-kappaB activation through PDGF signaling was investigated by electrophoretic mobility shift assay, specific NF-kappaB inhibitors, and the PDGF-receptor kinase inhibitor imatinib mesylate.RESULTS: IL-6, IL-8, CCL2, CCL5, and CCL7 production by orbital fibroblasts was increased by PDGF-BB stimulation, whereas IL-16, IL-1beta, and TNF-alpha production was not affected. PDGF-BB induced NF-kappaB activity in orbital fibroblasts, and both NF-kappaB inhibitors and imatinib mesylate reduced PDGF-BB-induced cytokine production. Similar, but less vigorous, effects of PDGF-BB on cytokine production were observed in lung and skin fibroblasts.CONCLUSIONS: PDGF-BB is a potent inducer of proinflammatory cytokines via the NF-kappaB pathway in orbital fibroblasts, whereas cytokine production by fibroblasts from other anatomic locations showed a moderate response. These data suggest a possible role for PDGF-BB in regulating orbital inflammation in GO and identify the PDGF signaling cascade as a therapeutic target in GO.
KW - Adult
KW - Aged
KW - Angiogenesis Inducing Agents/pharmacology
KW - Becaplermin
KW - Benzamides
KW - Cells, Cultured
KW - Cytokines/biosynthesis
KW - Electrophoretic Mobility Shift Assay
KW - Enzyme-Linked Immunosorbent Assay
KW - Female
KW - Fibroblasts/drug effects
KW - Graves Ophthalmopathy/metabolism
KW - Humans
KW - Imatinib Mesylate
KW - Lung/cytology
KW - Male
KW - Middle Aged
KW - NF-kappa B/metabolism
KW - Orbit/drug effects
KW - Piperazines/pharmacology
KW - Platelet-Derived Growth Factor/pharmacology
KW - Protein Kinase Inhibitors/pharmacology
KW - Protein-Tyrosine Kinases/antagonists & inhibitors
KW - Proto-Oncogene Proteins c-sis
KW - Pyrimidines/pharmacology
KW - Receptors, Platelet-Derived Growth Factor/antagonists & inhibitors
KW - Skin/cytology
U2 - 10.1167/iovs.09-4338
DO - 10.1167/iovs.09-4338
M3 - Article
C2 - 19797221
SN - 0146-0404
VL - 51
SP - 1002
EP - 1007
JO - Investigative ophthalmology & visual science
JF - Investigative ophthalmology & visual science
IS - 2
ER -